The effects of OKT3 anti-rejection therapy on in situ allograft infiltrating lymphocytes.
Kerr
P G
PG
Department of Nephrology, Prince Henry's Hospital, Melbourne, Australia.
Atkins
R C
RC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006084:Graft Rejection; D006801:Humans; D007167:Immunotherapy; D016030:Kidney Transplantation; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal